Since the breakout of COVID-19, the world has been racing against the clock to combat the pandemic as it spread havoc throughout the planet. One of the most important phases in the fight against the virus is the development of safe and effective vaccinations.
For over three years, China has achieved significant progress in COVID-19 vaccine development and taken real measures toward meeting its goal to make vaccinations a worldwide public benefit.
In terms of vaccine development, China is at the forefront.
Following the initial pandemic breakout at the end of 2019, Chinese researchers promptly disclosed the virus’s entire genome sequence in January 2020. Global scientists applauded the move to make the data public.
Jeremy Farrar, a medical researcher, and director at Wellcome Trust, a London-based nonprofit foundation on health research, called it a “possibly truly momentous moment in world public health-must be embraced” in a tweet.
READ MORE: Know Everything..!: What Meghan Markle Revealed About Kate Middleton, Know The Reality
The adenovirus vector vaccine created by a team led by Chinese military medical expert Chen Wei was licensed for clinical testing in China in March 2020.
The second set of testing began in April after the first phase was finished. According to the World Health Organization, China’s COVID-19 vaccine was the first in the world to enter the second phase of clinical testing at that time (WHO).
Concurrently, studies on the inactivated vaccine created by the China National Pharmaceutical Group (Sinopharm) and the inactive vaccine produced by the pharmaceutical business Sinovac in Beijing were conducted.
Strengthening international collaboration on vaccines
Due of the disparity in vaccine availability worldwide, China’s vaccinations have been essential in the global response to the epidemic.
The Sinopharm COVID-19 vaccine was approved for use in emergencies by the WHO in May 2021. It was the sixth vaccination to be worldwide licensed for use in an emergency and the first vaccine from China to receive formal recognition from the WHO.
According to WHO Director-General Dr. Tedros Adhanom Ghebreyesus, the vaccine was added to the list of emergency uses due to its “safety, effectiveness, and quality.”
The WHO granted authorization for the emergency use of another dormant vaccine made by Sinovac the following month.
The inactive vaccine from China had an advantage over other vaccines produced at the time by Moderna and Pfizer: it could be shipped and stored in a typical refrigerator at 2 to 8 degrees Celsius. Large quantities of vaccinations may be kept at low temperatures and are especially well suited for underdeveloped nations with insufficient transportation and vaccine storage facilities.
The WHO approved the CONVIDECIAL COVID-19 vaccine created by Chinese company CanSino Biologics for use in an emergency in May 2022. After Sinopharm and Sinopec, it was the third Chinese vaccine to be included on the WHO Emergency Use List.
Always be updated with us visit GeeksULTD for Real-time updates
